Shelter Pharma

Why is Shelter Pharma Ltd falling/rising?

As of 23-Jun, Shelter Pharma Ltd's stock price is rising to 29.25, reflecting a 2.24% increase. This positive momentum is driven by strong relative performance, increased investor interest, and potential for further gains as it approaches longer-term moving averages.

As of 23-Jun, Shelter Pharma Ltd's stock price is rising, currently at 29.25, reflecting an increase of 0.64 or 2.24%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 1.49% today, indicating strong relative performance. Additionally, it has experienced consecutive gains over the last two days, accumulating a total return of 4.39% during this period. <BR><BR>Investor participation has also increased, as evidenced by a 50% rise in delivery volume on June 19 compared to the 5-day average, suggesting growing interest in the stock. Furthermore, while the stock's current price is higher than its 5-day moving average, it remains lower than its longer-term moving averages (20-day, 50-day, 100-day, and 200-day), which may indicate potential for further upward movement as it approaches these averages. <BR><BR>Overall, these factors contribute to the positive momentum in Shelter Pharma Ltd's stock price.

Which are the latest news on Shelter Pharma?

What does Shelter Pharma do?

Shelter Pharma Ltd is a micro-cap company focused on manufacturing ayurvedic and herbal products, with a market cap of INR 50 Cr. It has a P/E ratio of 6.00 and a return on equity of 12.43%.

Overview:<BR>Shelter Pharma Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, primarily focused on manufacturing ayurvedic and herbal products.<BR><BR>History:<BR>Shelter Pharma Limited was incorporated on 12 October 2007, transitioning from a partnership firm named "M/s Shelter Pharma" to a public limited company. There is no recent sales and profit data reported.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 50 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 6.00<BR>Industry P/E: 34<BR>Dividend Yield: 0.69%<BR>Debt-Equity: 0.00<BR>Return on Equity: 12.43%<BR>Price-to-Book: 0.69<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Shelter Pharma?

Peers of Shelter Pharma include Samrat Pharma, Biofil Chemicals, Asston Pharmaceu, Kabra Drugs, Vivo Bio Tech, Veerhealth Care, Vasundhara Rasy., Mangalam Drugs, and Vista Pharma. Shelter Pharma has good management and capital structure ratings, with a 1-year return of -25.45%, better than Mangalam Drugs but worse than Kabra Drugs, which has the highest return at 86.81%.

Peers: The peers of Shelter Pharma are Samrat Pharma, Biofil Chemicals, Asston Pharmaceu, Kabra Drugs, Vivo Bio Tech, Veerhealth Care, Vasundhara Rasy., Mangalam Drugs, and Vista Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kabra Drugs and Shelter Pharma, while Average management risk is found at Samrat Pharma, Asston Pharmaceu, and the rest. Below Average management risk is present at Biofil Chemicals, Vivo Bio Tech, Veerhealth Care, Mangalam Drugs, and Vista Pharma. Growth is Excellent at Kabra Drugs, Good at Shelter Pharma, Below Average at Samrat Pharma, Biofil Chemicals, Asston Pharmaceu, Vivo Bio Tech, and Mangalam Drugs, while Average growth is seen at Veerhealth Care and the rest. Capital Structure is Excellent at Shelter Pharma, Good at Biofil Chemicals and Veerhealth Care, Average at Asston Pharmaceu, Below Average at Kabra Drugs, Vivo Bio Tech, Mangalam Drugs, and Vista Pharma, while the rest have a Capital Structure rating of Below Average.<BR><BR>Return Snapshot: Kabra Drugs has the highest 1-year return at 86.81%, while Mangalam Drugs has the lowest at -65.43%. Shelter Pharma's 1-year return of -25.45% is better than Mangalam Drugs but worse than Kabra Drugs. Additionally, peers with a negative six-month return include Samrat Pharma, Vivo Bio Tech, and Mangalam Drugs.

When is the next results date for Shelter Pharma Ltd?

The next results date for Shelter Pharma Ltd is 28 May 2026.

The next results date for Shelter Pharma Ltd is scheduled for 28 May 2026.

How has been the historical performance of Shelter Pharma?

Shelter Pharma has shown consistent growth in net sales and profitability, with net sales increasing from INR 30.06 crore in March 2022 to INR 50.66 crore in March 2025, and profit after tax rising from INR 1.84 crore to INR 7.24 crore during the same period. The company's financial performance reflects a strong upward trend across key metrics.

Answer:<BR>The historical performance of Shelter Pharma shows a consistent growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Shelter Pharma's net sales have steadily increased from INR 30.06 crore in March 2022 to INR 50.66 crore in March 2025. This growth is accompanied by a rise in total operating income, which reached INR 50.66 crore in March 2025, up from INR 30.06 crore in March 2022. The company's total expenditure also grew, amounting to INR 40.59 crore in March 2025, compared to INR 27.38 crore in March 2022. Operating profit (PBDIT) has shown significant improvement, rising from INR 2.68 crore in March 2022 to INR 10.08 crore in March 2025, reflecting an operating profit margin of 19.88% in the latest fiscal year. Profit before tax increased from INR 2.51 crore in March 2022 to INR 9.68 crore in March 2025, with profit after tax also rising from INR 1.84 crore to INR 7.24 crore during the same period. The company's total assets grew from INR 12.84 crore in March 2022 to INR 48.30 crore in March 2025, while total liabilities increased from INR 12.84 crore to INR 48.30 crore, indicating a proportional growth in both assets and liabilities. Cash flow from operating activities improved significantly, reaching INR 5.00 crore in March 2025, compared to a negative cash flow of INR 1.00 crore in March 2024. Overall, Shelter Pharma demonstrates a robust upward trend in its financial performance across key metrics.

Has Shelter Pharma declared dividend?

Shelter Pharma Ltd has declared a 3% dividend, with an ex-date of September 23, 2025. While recent total returns show positive growth in the short to medium term, longer-term returns have been stagnant with no dividends declared in the past few years.

Shelter Pharma Ltd has declared a 3% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 3%<BR>- Ex-date: 23 Sep 25<BR><BR>Dividend Yield: 0.67%.<BR><BR>Total Returns by Period:<BR>In the 3-month period, the price return was 9.9%, the dividend return was 0.75%, resulting in a total return of 10.65%.<BR><BR>In the 6-month period, the price return was 3.51%, the dividend return was 0.68%, leading to a total return of 4.19%.<BR><BR>For the 1-year period, the price return was 5.5%, the dividend return was 1.25%, which culminated in a total return of 6.75%.<BR><BR>Over the 2-year period, the price return was -3.95%, the dividend return was 1.32%, resulting in a total return of -2.63%.<BR><BR>In the 3-year period, there was no price return, no dividend return, and thus a total return of 0.0%.<BR><BR>For the 4-year period, there were no changes in price or dividends, leading to a total return of 0.0%.<BR><BR>In the 5-year period, again, there were no returns from price or dividends, resulting in a total return of 0.0%.<BR><BR>Overall, Shelter Pharma Ltd has declared a dividend, and while the recent total returns show positive growth in the short to medium term, longer-term returns have been stagnant with no dividends declared in the past few years.

Is Shelter Pharma overvalued or undervalued?

As of August 28, 2025, Shelter Pharma is considered undervalued with a valuation grade upgrade to very attractive, supported by a low PE ratio of 7.42 and an EV to EBIT of 5.03, significantly lower than its peers like Sun Pharma and Divi's Lab, despite a recent stock price decline.

As of 28 August 2025, Shelter Pharma's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued, especially when compared to its peers. Key ratios supporting this assessment include a PE ratio of 7.42, an EV to EBIT of 5.03, and a PEG ratio of 0.46, all of which are substantially lower than industry averages.<BR><BR>In comparison to its peers, Shelter Pharma stands out with a much lower PE ratio than Sun Pharma (33.18) and Divi's Lab (70.66), both of which are classified as expensive. Additionally, Shelter Pharma's EV to EBITDA ratio of 4.89 is significantly more attractive than that of its competitors, reinforcing its undervaluation. Despite a recent decline in stock price, Shelter Pharma has outperformed the Sensex over the past month, suggesting a potential rebound as market conditions stabilize.

How big is Shelter Pharma?

As of 24th July, Shelter Pharma Ltd has a market capitalization of 52.00 Cr, classifying it as a Micro Cap company, with no valid financial data available for Net Sales and Net Profit for the latest four quarters. Shareholder's Funds are 35.82 Cr and Total Assets are 37.88 Cr as of March 2024.

As of 24th July, <BR><BR>Market Cap: Shelter Pharma Ltd has a market capitalization of 52.00 Cr, classifying it as a Micro Cap company. <BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters. <BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 35.82 Cr and Total Assets valued at 37.88 Cr.

Who are the top shareholders of the Shelter Pharma?

The top shareholders of Shelter Pharma include promoters, with Shakil Nisarahmed Sabugar holding the largest stake at 15.23%. Individual investors own 43.24% of the company, and there are no mutual funds or foreign institutional investors involved.

The top shareholders of Shelter Pharma primarily consist of promoters, with Shakil Nisarahmed Sabugar holding the highest stake at 15.23%. Individual investors collectively own 43.24% of the company. There are no mutual funds or foreign institutional investors (FIIs) holding shares in Shelter Pharma, and there are no pledged promoter holdings.

What is the technical trend for Shelter Pharma?

As of May 30, 2025, Shelter Pharma's technical trend is mildly bearish, indicated by daily moving averages and weekly Bollinger Bands, despite a mildly bullish MACD and no clear signals from the RSI or Dow Theory.

As of 30 May 2025, the technical trend for Shelter Pharma has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly Bollinger Bands also reflect a bearish outlook. The MACD on the weekly chart is mildly bullish, but this is countered by the lack of signals from the RSI on both weekly and monthly time frames. Additionally, the Dow Theory shows no trend in both weekly and monthly perspectives. Overall, the current stance is mildly bearish, driven primarily by the daily moving averages and weekly Bollinger Bands.